

BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 20713

Title: Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male

subjects

Reviewer's code: 01568246 Reviewer's country: Norway Science editor: Ya-Juan Ma

Date sent for review: 2015-06-19 11:03

Date reviewed: 2015-07-13 17:36

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[] Grade A: Excellent	[Y] Grade A: Priority publishing	Google Search:	[] Accept
[Y] Grade B: Very good	[] Grade B: Minor language	[] The same title	[Y] High priority for
[] Grade C: Good	polishing	[] Duplicate publication	publication
[] Grade D: Fair	[] Grade C: A great deal of	[] Plagiarism	[] Rejection
[] Grade E: Poor	language polishing	[Y]No	[] Minor revision
	[] Grade D: Rejected	BPG Search:	[] Major revision
		[] The same title	
		[] Duplicate publication	
		[] Plagiarism	
		[Y]No	

COMMENTS TO AUTHORS

The purpose of the research was to determine whether sulforaphane (SF) will reduce/prevent hepatic abnormalities (measured as release of marker enzymes). The manuscript is well written. The Abstract gives a good overview of the objectives, the methods used, and the data obtained. The main results shows that the aim of the research has been reached. The authors have selected well known markers to evaluate the state of the liver, and are able to draw a relatively reliable conclusion with regard to the effects of the treatment of the (male) participants in the study. The animal (rat) studies also support the conclusion that SF improves liver function through reduction of oxidative stress. The data obtained are interesting and support earlier reports. On the other hand the effects of SF treatment are very small, and further experiments are needed to bring the project further. In a follow-up project it would in particular (as suggested by the authors) be of interest to determine the effects of higher doses of SF-precursor and longer trial periods. The authors should also extend the list of liver function markers. Minor point: The Discussion is good and reads well. However, parts of it could have been used in the Introduction. For a reader not very familiar with the molecular



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

mechanisms whereby SF acts it would have been an advantage to be informed in more detail about this topic in the Introduction. Such information is in the present version of the paper in the Discussion.